Total protein and α2-macroglobulin in lacrimal fluid in primary open-angle glaucoma at different levels of intraocular pressure before and after surgical treatment
https://doi.org/10.53432/2078-4104-2026-25-2-11-17
Abstract
PURPOSE. To study the total protein and α2-macroglobulin (α2-MG) levels in the lacrimal fluid (LF) of patients with primary open-angle glaucoma (POAG) depending on age, glaucoma stage, intra-ocular pressure (IOP) levels and after trabeculectomy.
METHODS. Analysis of the total protein (mg/ml) and α2-MG (nmol/min×ml) levels in LF was performed in 46 patients with POAG stages I–IV before and 7 days after sinus trabeculectomy.
RESULTS. The level of total protein in LF in patients with POAG before surgery was 2.23±0.13 mg/ml. A trend toward a decrease with age (r=0.32) and an increase with glaucoma progression (r=0.39) was observed: stage I — 1.80±0.14 mg/ml, stage II — 1.96±0.18 mg/ml, stage III — 2.81±0.23 mg/ml. After sinus trabeculectomy, IOP decreased from 23.5±6.1 to 14.6±4.2 mm Hg. The decrease in the total protein level was 0.05 mg/ml (from 2.23±0.13 to 2.18±0.24 mg/ml), with a correlation coefficient of 0.24. The preoperative α2-MG level was 0.46±0.07 nmol/min×ml, with no significant correlation with glaucoma stage (r=0.03) or IOP level (r=–0.26). A correlation with patient age was identified (r=0.64). Analysis of α2-MG levels in relation to IOP changes over time demonstrated an inverse correlation between IOP and α2-MG levels before and after surgery: a decrease in IOP was accompanied by a non-significant increase in α2-MG of 0.13 nmol/min×ml (from 0.46±0.07 to 0.60±0.12 nmol/min×ml), r=0.29.
CONCLUSION. The level of total protein in LF is an important parameter in POAG, correlating with patient age and glaucoma stage. No significant correlation of α2-MG level in LF with glaucoma stage or IOP was observed. Surgical IOP reduction was associated with a decrease in total protein level and an increase in α2-MG level, both demonstrating weak correlations.
About the Authors
S. Yu. Petrov
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Dr. Sci. (Med.), Head of the Glaucoma Department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
T. A. Pavlenko
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Cand. Sci. (Med.), Head of the Department of Pathophysiology and Biochemistry
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
O. A. Lisovskaya
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
researcher at the Department of Pathophysiology and Biochemistry
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
O. I. Markelova
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
junior researcher at the Glaucoma Department
14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062
References
1. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121(11):2081-2090. https://doi.org/10.1016/j.ophtha.2014.05.013
2. Neroev V.V., Mikhaylova L.A., Malishevskaya T.N., Petrov S.Yu., Filippova O.M. Glaucoma epidemiology in the Russian Federation. Russian ophthalmological journal 2024; 17(3): 7-12. https://doi.org/10.21516/2072-0076-2024-17-3-7-12
3. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90(3):262-267. https://doi.org/10.1136/bjo.2005.081224
4. Moshetova L.K., Volkov O.A. Modern conception of lacrimal fluid, it’s role in diagnostics. RMJ Clinical Ophthalmology 2004; 5(4):138-141.
5. Casemore R.K., Wolffsohn J.S., Dutta D. Human Tear Protein Analysis Using a Quantitative Microfluidic System: A Pilot Study. Eye Contact Lens 2023; 49(11):498-504. https://doi.org/10.1097/ICL.0000000000001036
6. Gachon A.M., Richard J., Dastugue B. Human tears: normal protein pattern and individual protein determinations in adults. Curr Eye Res 1982; 2(5):301-308. https://doi.org/10.3109/02713688209000774
7. Pavlenko T.A., Chesnokova N.B., Davydova N.G., et al. Level of tear endothelin-1 and plasminogen in patients with glaucoma and prolife-rative diabetic retinopathy. Vestnik Oftal’mologii 2013; 129(4): 20-23.
8. Marola O.J., Syc-Mazurek S.B., Howell G.R., Libby R.T. Endothelin 1-induced retinal ganglion cell death is largely mediated by JUN activation. Cell Death Dis 2020; 11(9):811. https://doi.org/10.1038/s41419-020-02990-0
9. Petrov S.Yu., Pavlenko T.A., Lisovskaya O.A., Markelova O.I., Epkhieva A.D. Study of endothelin-1 levels in tear fluid in primary open-angle glaucoma. National Journal glaucoma 2025; 24(1):8-13. https://doi.org/10.53432/2078-4104-2025-24-1-8-13
10. Barcelona P.F., Saragovi H.U. A Pro-Nerve Growth Factor (proNGF) and NGF Binding Protein, alpha2-Macroglobulin, Differentially Regulates p75 and TrkA Receptors and Is Relevant to Neurodegeneration Ex Vivo and In Vivo. Mol Cell Biol 2015; 35(19):3396-3408. https://doi.org/10.1128/MCB.00544-15
11. Liebl D.J., Koo P.H. Serotonin-activated alpha 2-macroglobulin inhibits neurite outgrowth and survival of embryonic sensory and cerebral cortical neurons. J Neurosci Res 1993; 35(2):170-182. https://doi.org/10.1002/jnr.490350207
12. Sathe S., Sakata M., Beaton A.R., Sack R.A. Identification, origins and the diurnal role of the principal serine protease inhibitors in human tear fluid. Curr Eye Res 1998; 17(4):348-362. https://doi.org/10.1080/02713689808951215
13. Chesnokova N.B., Pavlenko T.A., Beznos O.V., et al. Multifunctional protein аlpha2-macroglobulin in tear fluid and blood serum of patients with glaucoma. Ophthalmology in Russia 2022; 19(4):835-840. https://doi.org/10.18008/1816-5095-2022-4-835-840
14. Fabrizi C., Businaro R., Lauro G.M., Fumagalli L. Role of alpha2- macroglobulin in regulating amyloid beta-protein neurotoxicity: protective or detrimental factor? J Neurochem 2001; 78(2):406-412. https://doi.org/10.1046/j.1471-4159.2001.00419.x
15. Qiu Z., Strickland D.K., Hyman B.T., Rebeck G.W. Alpha2- macroglobulin enhances the clearance of endogenous soluble betaamyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem 1999; 73(4):1393-1398. https://doi.org/10.1046/j.1471-4159.1999.0731393.x
16. Wyatt A.R., Constantinescu P., Ecroyd H., Dobson C.M., Wilson M.R., Kumita J.R., et al. Protease-activated alpha-2-macroglobulin can inhibit amyloid formation via two distinct mechanisms. FEBS Lett 2013; 587(5):398-403. https://doi.org/10.1016/j.febslet.2013.01.020
17. Shi Z., Rudzinski M., Meerovitch K., Lebrun-Julien F., Birman E., Di Polo A., et al. Alpha2-macroglobulin is a mediator of retinal ganglion cell death in glaucoma. J Biol Chem 2008; 283(43):29156-29165. https://doi.org/10.1074/jbc.M802365200
18. Clinical Gidelines «Primary open angle glaucoma». 2020 (16.02.2021), Approved by the Ministry of Health of the Russian Federation.
19. Chuang W.H., Liu P.C., Hung C.Y., Lee K.K. Purification, characterization and molecular cloning of alpha-2-macroglobulin in cobia, Rachycentron canadum. Fish Shellfish Immunol 2014; 41(2): 346-355. https://doi.org/10.1016/j.fsi.2014.09.016
20. Vasilyeva T.G., Dobrogorskaya L.N., Kraeva L.N., Goncharova V.P. Alpha-2-macroglobulin in cerebrospinal fluid in neurosurgical diseases. Problems of Medical Chemistry 1989; 35(6):48-51.
Review
For citations:
Petrov S.Yu., Pavlenko T.A., Lisovskaya O.A., Markelova O.I. Total protein and α2-macroglobulin in lacrimal fluid in primary open-angle glaucoma at different levels of intraocular pressure before and after surgical treatment. National Journal glaucoma. 2026;25(2):11-17. (In Russ.) https://doi.org/10.53432/2078-4104-2026-25-2-11-17
Views:
75
JATS XML
Email this article 